The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Kava

  • The plant or substance description, clinical indications, evidence of therapeutic efficacy, mechanisms of therapeutic actions, dosages and regimens, different commercially available preparations, and adverse effects and toxicities are described for melatonin, St John's wort, valerian, and kava-kava [1].

High impact information on Kava

  • Heavy chronic consumption of kava (Piper methysticum) is associated with a pellagroid dermopathy that has been attributed to niacin deficiency [2].
  • Kava when used with alprazolam has resulted in coma [3].
  • Kava produced significant reductions (approximately 40%) in CYP2E1 only (difference, -0.192; 95% CI, -0.325 to -0.060) [4].
  • Kava (Piper methysticum) increases 'off' periods in Parkinson patients taking levodopa and can cause a semicomatose state when given concomitantly with alprazolam [5].
  • The search terms used were kava, kawa, kavain, Piper methysticum, and Rauschpfeffer (German term for Piper methysticum) [6].

Biological context of Kava


Anatomical context of Kava


Associations of Kava with chemical compounds


Gene context of Kava


Analytical, diagnostic and therapeutic context of Kava


  1. Over-the-counter psychotropics: a review of melatonin, St John's wort, valerian, and kava-kava. Heiligenstein, E., Guenther, G. Journal of American college health : J of ACH. (1998) [Pubmed]
  2. Kava-induced dermopathy: a niacin deficiency? Ruze, P. Lancet (1990) [Pubmed]
  3. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Miller, L.G. Arch. Intern. Med. (1998) [Pubmed]
  4. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Gurley, B.J., Gardner, S.F., Hubbard, M.A., Williams, D.K., Gentry, W.B., Khan, I.A., Shah, A. Clin. Pharmacol. Ther. (2005) [Pubmed]
  5. Interactions between herbal medicines and prescribed drugs: a systematic review. Izzo, A.A., Ernst, E. Drugs (2001) [Pubmed]
  6. Efficacy of kava extract for treating anxiety: systematic review and meta-analysis. Pittler, M.H., Ernst, E. Journal of clinical psychopharmacology. (2000) [Pubmed]
  7. Extracts of kava (Piper methysticum) induce acute anxiolytic-like behavioral changes in mice. Garrett, K.M., Basmadjian, G., Khan, I.A., Schaneberg, B.T., Seale, T.W. Psychopharmacology (Berl.) (2003) [Pubmed]
  8. Effects of oxazepam and an extract of kava roots (Piper methysticum) on event-related potentials in a word recognition task. Münte, T.F., Heinze, H.J., Matzke, M., Steitz, J. Neuropsychobiology (1993) [Pubmed]
  9. Effects of kava (Kava-kava, 'Awa, Yaqona, Piper methysticum) on c-DNA-expressed cytochrome P450 enzymes and human cryopreserved hepatocytes. Zou, L., Henderson, G.L., Harkey, M.R., Sakai, Y., Li, A. Phytomedicine (2004) [Pubmed]
  10. Effects of kava-kava extract on the sleep-wake cycle in sleep-disturbed rats. Shinomiya, K., Inoue, T., Utsu, Y., Tokunaga, S., Masuoka, T., Ohmori, A., Kamei, C. Psychopharmacology (Berl.) (2005) [Pubmed]
  11. Kava and dopamine antagonism. Schelosky, L., Raffauf, C., Jendroska, K., Poewe, W. J. Neurol. Neurosurg. Psychiatr. (1995) [Pubmed]
  12. Kavapyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of rat brain. Jussofie, A., Schmiz, A., Hiemke, C. Psychopharmacology (Berl.) (1994) [Pubmed]
  13. Potential health risks of complementary alternative medicines in cancer patients. Werneke, U., Earl, J., Seydel, C., Horn, O., Crichton, P., Fannon, D. Br. J. Cancer (2004) [Pubmed]
  14. Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Raucy, J.L. Drug Metab. Dispos. (2003) [Pubmed]
  15. Pharmacokinetics and disposition of the kavalactone kawain: interaction with kava extract and kavalactones in vivo and in vitro. Mathews, J.M., Etheridge, A.S., Valentine, J.L., Black, S.R., Coleman, D.P., Patel, P., So, J., Burka, L.T. Drug Metab. Dispos. (2005) [Pubmed]
  16. Inhibition of platelet MAO-B by kava pyrone-enriched extract from Piper methysticum Forster (kava-kava). Uebelhack, R., Franke, L., Schewe, H.J. Pharmacopsychiatry (1998) [Pubmed]
  17. Novel compounds from Piper methysticum Forst (Kava Kava) roots and their effect on cyclooxygenase enzyme. Wu, D., Nair, M.G., DeWitt, D.L. J. Agric. Food Chem. (2002) [Pubmed]
  18. Superheated water chromatography-nuclear magnetic resonance spectroscopy of kava lactones. Chienthavorn, O., Smith, R.M., Wilson, I.D., Wright, B., Lenz, E.M. Phytochemical analysis : PCA. (2005) [Pubmed]
  19. Analysis of kavalactones from Piper methysticum (kava-kava). Bilia, A.R., Scalise, L., Bergonzi, M.C., Vincieri, F.F. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. (2004) [Pubmed]
WikiGenes - Universities